» Articles » PMID: 15069027

Transgenic Rescue of Neurogenic Atrophy in the Nmd Mouse Reveals a Role for Ighmbp2 in Dilated Cardiomyopathy

Overview
Journal Hum Mol Genet
Date 2004 Apr 8
PMID 15069027
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Immunoglobulin mu binding protein 2 (IGHMBP2) is a DNA/RNA helicase with a putative role in transcriptional regulation and splicing. A recessive mutation of the Ighmbp2 gene in neuromuscular degeneration (nmd) mice causes progressive neurogenic atrophy of limb muscles. Affected mice show significant loss of motor neurons with large caliber axons and a moderate reduction of neurons with small caliber axons in the ventral nerve roots of the spinal cord. To investigate the role of Ighmbp2 in the pathogenesis of neuromuscular degeneration, we generated two independent lines of transgenic mice expressing the full-length Ighmbp2 cDNA specifically in neurons. Histopathological evaluation of L4 ventral nerve roots revealed that transgenic expression of the Ighmbp2 cDNA prevented primary motor neuron degeneration, while restoring the normal axonal morphology and density in nmd mice. A similar neuronal improvement is found in mutant mice carrying the CAST/EiJ-derived modifier of nmd (Mnm(C)). Intriguingly, both the transgenic and modified nmd mice went on to develop a previously unobserved cardiac and skeletal myopathy. Necropsy of nmd mice in end-stage heart failure revealed a primary dilated cardiomyopathy with secondary respiratory failure that was confirmed by in vivo ECG and echocardiographic measures. Our results suggest that reduced levels of IGHMBP2 in nmd mice compromise the integrity and function not only of motor neurons but also of skeletal and cardiac myocytes. These findings highlight the important role of IGHMBP2 in the maintenance and survival of these terminally differentiated cell types.

Citing Articles

Activators of the 26S proteasome when protein degradation increases.

Lee D Exp Mol Med. 2025; 57(1):41-49.

PMID: 39779978 PMC: 11799193. DOI: 10.1038/s12276-024-01385-x.


Cardiomyopathy: pathogenesis and therapeutic interventions.

Huang S, Li J, Li Q, Wang Q, Zhou X, Chen J MedComm (2020). 2024; 5(11):e772.

PMID: 39465141 PMC: 11502724. DOI: 10.1002/mco2.772.


Disease Mechanisms and Therapeutic Approaches in SMARD1-Insights from Animal Models and Cell Models.

Jablonka S, Yildirim E Biomedicines. 2024; 12(4).

PMID: 38672198 PMC: 11048220. DOI: 10.3390/biomedicines12040845.


Clinically relevant mouse models of Charcot-Marie-Tooth type 2S.

Martin P, Holbrook S, Hicks A, Hines T, Bogdanik L, Burgess R Hum Mol Genet. 2022; 32(8):1276-1288.

PMID: 36413117 PMC: 10077500. DOI: 10.1093/hmg/ddac283.


The Ighmbp2D564N mouse model is the first SMARD1 model to demonstrate respiratory defects.

Smith C, Lorson M, Ricardez Hernandez S, Al Rawi Z, Mao J, Marquez J Hum Mol Genet. 2021; 31(8):1293-1307.

PMID: 34726235 PMC: 9029233. DOI: 10.1093/hmg/ddab317.


References
1.
Miao M, Chan S, Fletcher G, Hew C . The rat ortholog of the presumptive flounder antifreeze enhancer-binding protein is a helicase domain-containing protein. Eur J Biochem. 2000; 267(24):7237-46. DOI: 10.1046/j.1432-1327.2000.01836.x. View

2.
Elsasser A, Suzuki K, Schaper J . Unresolved issues regarding the role of apoptosis in the pathogenesis of ischemic injury and heart failure. J Mol Cell Cardiol. 2000; 32(5):711-24. DOI: 10.1006/jmcc.2000.1125. View

3.
Kang P, Izumo S . Apoptosis and heart failure: A critical review of the literature. Circ Res. 2000; 86(11):1107-13. DOI: 10.1161/01.res.86.11.1107. View

4.
Chien K . Genomic circuits and the integrative biology of cardiac diseases. Nature. 2000; 407(6801):227-32. DOI: 10.1038/35025196. View

5.
Kamisago M, Sharma S, DePalma S, Solomon S, Sharma P, McDonough B . Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med. 2000; 343(23):1688-96. DOI: 10.1056/NEJM200012073432304. View